VEGFA - vascular endothelial growth factor A Gene

Also Known as VEGF

Species: Felis catus

Gene Type: protein coding
Gene ID: 493845

VEGFA Products (1)

mRNA Protein Name
NM_001009854.1 NP_001009854.1 vascular endothelial growth factor A precursor
Protein Preferred Names Protein Names

vascular endothelial growth factor A

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive MoleculesInhibitory Antibodies (4)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P9906 Bevacizumab Inhibitor ≥99.0% Unkown
HY-P9906A Bevacizumab (Anti-VEGFA) Inhibitor 99.07% Unkown
HY-P99116 Faricimab Inhibitor 97.97% Unkown
HY-P9973 Brolucizumab Inhibitor 99.90% Unkown

Clinical Phase

Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Phase
HY-P10284 S7 98.25% Phase 4
HY-B1788 Taurocholic acid 99.83% Phase 2
HY-N0545 Taurocholic acid sodium Agonist 99.82% Phase 2
HY-P3369 Gersizangitide 97.16% Phase 2
HY-B1788R Taurocholic acid (Standard) 99.91% Phase 2
Bioactive MoleculesInhibitory Antibodies (12)
Cat. No. Product Name Effect
Purity Phase
HY-P99675 Ivonescimab Inhibitor 99.13% Phase 4
HY-P99830 Conbercept Inhibitor 98.42% Phase 4
HY-P991097 Pumitamig Inhibitor 99.6% Phase 3
HY-P99576 Tarcocimab Inhibitor 98.35% Phase 3
HY-P991033 Tovecimig 97.39% Phase 3
HY-P990082 Suvemcitug Inhibitor 96% Phase 3
HY-P991416 BAT5906 Inhibitor / Phase 3
HY-P991418 MW02 Inhibitor / Phase 3
HY-P99330 Vanucizumab Inhibitor 95.12% Phase 2
HY-P991738 LM-299 Inhibitor 95.78% Phase 2
HY-P990689 Zifibancimig Inhibitor 99.00% Phase 2
HY-P991417 LYN00101 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (37)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-10799 EG00229 trifluoroacetate Antagonist 98.03% Unkown
HY-117661 SPHINX31 Inhibitor 99.25% Unkown
HY-B1131 Taurocholic acid sodium salt hydrate 98.51% Unkown
HY-N2187 Deoxyshikonin 99.96% Unkown
HY-124593 PTC299 Inhibitor 99.71% Unkown
HY-144707 AK-778-XXMU 99.96% Unkown
HY-P10831 GNQWFI Antagonist 99.45% Unkown
HY-115746 Dimethyl-bisphenol A Inhibitor 99.78% Unkown
HY-N7043 Isosilybin A 99.63% Unkown
HY-N0545R Taurocholic acid sodium (Standard) Agonist 97.91% Unkown
HY-N10336 Notoginsenoside R4 99.90% Unkown
HY-138647 TGP-377/421 Inhibitor 98.17% Unkown
HY-W653842 Taurocholic acid-d8 sodium Agonist 98.83% Unkown
HY-101931 hVEGF-IN-1 Inhibitor 99.25% Unkown
HY-182700 NRPa-308 Inhibitor 98.96% Unkown
HY-P10971 Nef-M1 98.87% Unkown
HY-124722 OHM1 Inhibitor / Unkown
HY-149886 HIF-2α-IN-9 Inhibitor / Unkown
HY-163760 ZM-32 Inhibitor / Unkown
HY-168560 MMP Inhibitor 4 Inhibitor / Unkown
HY-176805 TGP-377 / Unkown
HY-179350 EG01449 Free acid Inhibitor / Unkown
HY-179350A EG01449 Inhibitor / Unkown
HY-182639 AM9928 Inhibitor / Unkown
HY-18333 EG00229 Inhibitor / Unkown
HY-N0545S2 Taurocholic acid-d4-1 sodium / Unkown
HY-N19872 Mukurozioside IIb / Unkown
HY-N19873 Mukurozioside IIa / Unkown
HY-P10550 VGB4 Antagonist / Unkown
HY-P3990 Coibamide A / Unkown
HY-RS15635 VEGFA Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-128446 CAY10781 Inhibitor 98.04% Unkown
HY-174510 Human VEGFA mRNA / Unkown
HY-B1788S2 Taurocholic acid-d5 / Unkown
HY-RS16537 Vegfa Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS22968 Vegfa Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W653893 Taurocholic acid-d5 sodium Agonist / Unkown
Bioactive MoleculesInhibitory Antibodies (8)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P9920A Ramucirumab (anti-VEGFR) Antagonist 99.9% Unkown
HY-P9951A Ranibizumab (anti-VEGF) Inhibitor 99.60% Unkown
HY-P990148 Anti-Mouse VEGF-A Antibody (2G11-2A05) Inhibitor 97.40% Unkown
HY-P992139 Valancitug Inhibitor 97.61% Unkown
HY-P991625 VX70 / Unkown
HY-P992323 BI-836880 Inhibitor / Unkown
HY-P992511 CS2009 Inhibitor / Unkown
HY-P992518 Pumitamig (Mouse IgG2a) Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens VEGFA NCBI NCBI:7422